FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Clinical effects of a combination of phenylbutazone and omep...
Equine veterinary journal2023; 56(3); 562-572; doi: 10.1111/evj.13962

Clinical effects of a combination of phenylbutazone and omeprazole on chronic lameness in Mongolian horses.

Abstract: Phenylbutazone (PBZ) is the most commonly used drug to treat symptoms of lameness in horses; however, it is associated with adverse effects such as gastric ulcer syndrome (EGUS). Interestingly, many practitioners prescribe omeprazole (OME) concurrently with PBZ to prevent the development of EGUS. However, the efficacy and safety of this practice in Mongolian horses with chronic lameness remain unknown. Objective: To evaluate the clinical effects of a combination of PBZ and OME on chronic lameness in Mongolian horses. Methods: Randomised block experimental design. Methods: Eighteen Mongolian horses with lameness score was ≥3 points, were divided into three treatment groups, with six horses in each group: placebo (CON), PBZ (4.4 mg/kg PO q. 24 h), or PBZ plus OME (4 mg/kg PO q. 24 h; PBZ + OME) in a randomised block design based on the initial lameness score. The horses were treated for 15 days. During this period, weekly gastroscopy, and physiological and biochemical tests were performed. Results: Both PBZ (median 1.0, interquartile range [IQR]: 0.8-1.3; p = 0.01) and PBZ + OME (median 1.0, IQR: 1.0-1.0; p = 0.01) significantly decreased the lameness score compared with before administration. In addition, PBZ significantly increased the equine glandular gastric disease (EGGD) score (3.0 ± 0.6, p < 0.001), GT-17 content (293.4 ± 21.8 pg/mL, p < 0.001), and pepsinogen-1 (PG1) content (295.3 ± 38.3 ng/mL, p < 0.001) compared with CON or PBZ + OME. However, it significantly reduced the total protein (53.6 ± 1.5 g/L, p < 0.05) and albumin (25.5 ± 1.8 g/L, p < 0.05) contents. Nevertheless, compared with PBZ, PBZ + OME significantly decreased the EGGD score (0.3 ± 0.5, p < 0.001) and significantly increased the gastric fluid pH (7.3 ± 0.5, p < 0.001), total protein content (62.5 ± 4.6 g/L, p = 0.009), and albumin content (29.4 ± 1.1 g/L, p = 0.004). Meanwhile, they significantly diminished the gastrin 17 (GT-17) (162.0 ± 21.0 pg/mL, p < 0.001) and PG1 (182.4 ± 22.5 ng/mL, p < 0.001) contents. Conclusions: Individual differences in horses were larger, but the sample size was small. There was larger interval between observations for each index. Conclusions: Compared with PBZ alone, PBZ + OME had no therapeutic effect on chronic lameness; however, it reduced the occurrence of EGGD in Mongolian horses. Horses may be protected against chronic lameness and PBZ-induced EGGD by increasing the pH value, decreasing serum PG1 and GT-17 content, and preventing the reduction of myeloperoxidase content.
© 2023 EVJ Ltd.
Get Full Text
Publication Date: 2023-06-19 PubMed ID: 37337455DOI: 10.1111/evj.13962Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research explores the effects of a combination of Phenylbutazone and Omeprazole on chronic lameness in Mongolian horses. The study found that while the combination didn’t offer an improvement on lameness itself, it reduced the occurrence of equine glandular gastric disease, a common side-effect of Phenylbutazone treatment.

Objective

Mongolian horses suffering from chronic lameness have routinely been treated with Phenylbutazone (PBZ), but PBZ usage is often accompanied by adverse reactions like equine glandular gastric disease (EGGD). In some cases, Omeprazole (OME) is administered along with PBZ to mitigate these side effects. This study aims to examine the clinical impact of using both PBZ and OME for treating chronic lameness in Mongolian horses.

Methods

  • The researchers used a Randomised block experimental design in their study.
  • They selected 18 Mongolian horses, each suffering from chronic lameness. These horses were further divided into three groups of six: placebo, PBZ, and PBZ + OME.
  • Horses were subjected to their respective treatments for 15 days.
  • During this period, weekly gastroscopy exams were performed, along with various physiological and biochemical analyses.

Results

  • The PBZ-only and PBZ+OME treatment groups showed a significant improvement in lameness compared to pre-administration.
  • PBZ-only treatments increased the EGGD scores, decreased total protein and albumin contents, and elevated GT-17 and PG1 content in comparison to the placebo group and the PBZ+OME group.
  • Contrarily, the group receiving PBZ+OME treatment showed a significant decline in EGGD score, an increase in gastric fluid pH, total protein, and albumin content, and decreased GT-17 and PG1 content compared to the PBZ-only group.

Conclusions

The study concludes that the combination of PBZ and OME does not improve chronic lameness in Mongolian horses relative to PBZ alone. However, PBZ+OME treatment reduces the incidence of PBZ-induced EGGD in these horses. The findings suggest that these horses possibly could be protected against chronic lameness and EGGD by increasing the pH value, reducing serum PG1 and GT-17 content, and preventing the reduction of myeloperoxidase content. The researchers also acknowledge limitations such as small sample size and variability among the horses, and intervals between the observations of different indicators.

Cite This Article

APA
Li Z, Du S, Wang X, Zhang L, Liu X, Fan Q, Yang H, Gao R. (2023). Clinical effects of a combination of phenylbutazone and omeprazole on chronic lameness in Mongolian horses. Equine Vet J, 56(3), 562-572. https://doi.org/10.1111/evj.13962

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 56
Issue: 3
Pages: 562-572

Researcher Affiliations

Li, Zhengyi
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Du, Shan
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Wang, Xiaomin
  • Agriculture and Animal Husbandry Bureau, Karaqin Banner, Chifeng, China.
Zhang, Lanxin
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Liu, Xinyu
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Fan, Quanrong
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Yang, Huidi
  • College of Basic Medicine, Inner Mongolia Medical University, Hohhot, China.
Gao, Ruifeng
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.

MeSH Terms

  • Horses
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal
  • Omeprazole
  • Lameness, Animal / drug therapy
  • Lameness, Animal / prevention & control
  • Phenylbutazone / therapeutic use
  • Phenylbutazone / adverse effects
  • Stomach Ulcer / drug therapy
  • Stomach Ulcer / prevention & control
  • Stomach Ulcer / veterinary
  • Horse Diseases / drug therapy
  • Horse Diseases / prevention & control
  • Horse Diseases / chemically induced
  • Albumins / adverse effects

Grant Funding

  • 32160247 / National Natural Science Foundation of China
  • 32160856 / National Natural Science Foundation of China
  • 2020MS03059 / Natural Science Foundation of Inner Mongolia
  • SHANXUE project of Inner Mongolia Medical University

References

This article includes 56 references
  1. Duz M, Marshall JF, Parkin TD. Proportion of nonsteroidal anti‐inflammatory drug prescription in equine practice.. Equine Vet J 2019;51:147–53.
  2. Tobin T, Chay S, Kamerling S, Woods WE, Weckman TJ, Blake JW. Phenylbutazone in the horse: a review.. J Vet Pharmacol Ther 1986;9:1–25.
  3. Lees P, Creed RF, Gerring EE, Gould PW, Humphreys DJ, Maitho TE. Biochemical and haematological effects of phenylbutazone in horses.. Equine Vet J 1983;15:158–67.
  4. Gunson DE, Soma LR. Renal papillary necrosis in horses after phenylbutazone and water deprivation.. Vet Pathol 1983;20:603–10.
  5. Read WK. Renal medullary crest necrosis associated with phenylbutazone therapy in horses.. Vet Pathol 1983;20:662–9.
  6. Mackay RJ, French TW, Nguyen HT, Mayhew IG. Effects of large doses of phenylbutazone administration to horses.. Am J Vet Res 1983;44:774–80.
  7. Snow DH, Douglas TA, Thompson H, Parkins JJ, Holmes PH. Phenylbutazone toxicosis in equidae: a biochemical and pathophysiological study.. Am J Vet Res 1981;42:1754–9.
  8. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID‐induced mucosal damage.. Arthritis Res Ther 2013;15(S3):S5.
  9. Vatistas NJ, Snyder JR, Nieto J, Thompson D, Pollmeier M, Holste J. Acceptability of a paste formulation and efficacy of high dose omeprazole in healing gastric ulcers in horses maintained in race training.. Equine Vet J 1999;31(S29):71–6.
  10. MacAllister CG, Sifferman RL, McClure SR, White GW, Vatistas NJ, Holste JE. Effects of omeprazole paste on healing of spontaneous gastric ulcers in horses and foals: a field trial.. Equine Vet J 1999;31(S31):77–80.
  11. Andrews FM, Sifferman RL, Bernard W, Hughes FE, Holste JE, Daurio CP. Efficacy of omeprazole paste in the treatment and prevention of gastric ulcers in horses.. Equine Vet J 1999;31(S31):81–6.
  12. Collins L, Tyler D. Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome and its prevention with synthetic prostaglandin E2.. Am J Vet Res 1985;46:1605–15.
  13. American Association of Equine Practitioners (AAEP). Lameness scale. Definition and classification of lameness.. In: Guide for veterinary service and judging of equestrian events. 4th ed. Lexington, KY: American Association of Equine Practitioners; 1991. p. 19.
  14. Andrews F, Bernard W, Byars D, Cohen N, Divers T, MacAllister C. Recommendations for the diagnosis and treatment of equine gastric ulcer syndrome (EGUS).. Equine Vet Educ 1999;11(5):262–72.
  15. Sykes BW, Hewetson M, Hepburn RJ, Luthersson N, Tamzali Y. European College of Equine Internal Medicine Consensus Statement – Equine Gastric Ulcer Syndrome in adult horses.. J Vet Intern Med 2015;29:1288–99.
  16. Ricord M, Andrews FM, Yñiguez FJ, Keowen M, Garza JF, Paul L. Impact of concurrent treatment with omeprazole on phenylbutazone‐induced equine gastric ulcer syndrome (EGUS).. Equine Vet J 2021;53(2):356–63.
  17. MacAllister CG, Morgan SJ, Borne AT, Pollet RA. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses.. J Am Vet Med Assoc 1993;202:71–7.
  18. Raidal SL, Andrews FM, Nielsen SG, Trope G. Pharmacokinetic and pharmacodynamic effects of two omeprazole formulations on stomach pH and gastric ulcer scores.. Equine Vet J 2017;49(6):802–9.
  19. Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton‐pump inhibitors with nonsteroidal anti‐inflammatory drugs: risks versus benefits.. J Pain Res 2018;11:361–74.
  20. Sykes BW, Sykes KM, Hallowell GD. A comparison of two doses of omeprazole in the treatment of equine gastric ulcer syndrome: a blinded, randomised, clinical trial.. Equine Vet J 2014;46:416–21.
  21. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W. Proton pump inhibitors exacerbate NSAID‐induced small intestinal injury by inducing dysbiosis.. Gastroenterology 2011;141:1314–1322.e5.
  22. Whitfield‐Cargile CM, Chamoun‐Emanuelli AM, Cohen ND, Richardson LM, Ajami NJ, Dockery HJ. Differential effects of selective and non‐selective cyclooxygenase inhibitors on fecal microbiota in adult horses.. PLoS One 2018;13:e0202527.
  23. Soma LR, Uboh CE, Maylin GM. The use of phenylbutazone in the horse.. J Vet Pharmacol Ther 2012;35:1–12.
  24. Hu HH, MacAllister CG, Payton ME, Erkert RS. Evaluation of the analgesic effects of phenylbutazone administered at a high or low dosage in horses with chronic lameness.. J Am Vet Med Assoc 2005;22:414–7.
  25. Toutain PL, Autefage A, Legrand C, Alvinerie M. Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling.. J Vet Pharmacol Ther 1994;17:459–69.
  26. Jamieson J, Kutryk M. Studies on the effect of phenylbutazone and salicylate on the rates of synthesis of albumin and acute‐phase α1‐acid glycoprotein by rat liver slices.. Biochem Med 1980;23:293–301.
  27. Cohen ND, Carter GK, Mealey RH, Taylor TS. The recognition and medical management of right dorsal colitis in horses.. Vet Med 1995;9:272–6.
  28. Rainsford K, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production.. Dig Dis Sci 1982;2:624–35.
  29. Mahmud T, Rafi SS, Scott DL, Wrigglesworth JM, Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation.. Arthritis Rheum 1996;39:1998–2003.
  30. Goddard PJ, Hills BA, Lichtenberger LM. Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity?. American journal of physiology‐gastrointestinal and liver Phys Ther 1987;252:G421–30.
  31. Goddard PJ, Kao Y‐CJ, Lichtenberger LM. Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel.. Gastroenterology 1990;98:361–70.
  32. Martínez Aranzales JR, Cândido de Andrade BS, Silveira Alves GE. Orally administered phenylbutazone causes oxidative stress in the equine gastric mucosa.. J Vet Pharmacol Ther 2015;38:257–64.
  33. El‐Ashker M, El‐Khodery S, Metwally N, Hussein H, El‐Boshy M. Prognostic significance of oxidative stress markers in colitis associated with phenylbutazone administration in draft horses.. J Equine Vet 2012;32:146–52.
  34. McConnico RS, Morgan TW, Williams CC, Hubert JD, Moore RM. Pathophysiologic effects of phenylbutazone on the right dorsal colon in horses.. Am J Vet Res 2008;69:1496–505.
  35. Sánchez S, Martín MJ, Ortiz P, Motilva V, Alarcón de la Lastra C. Effects of dipyrone on inflammatory infiltration and oxidative metabolism in gastric mucosa: comparison with acetaminophen and diclofenac.. Dig Dis Sci 2002;47:1389–98.
  36. Murakami K, Okajima K, Harada N, Isobe H, Liu W, Johno M. Plaunotol prevents indomethacin‐induced gastric mucosal injury in rats by inhibiting neutrophil activation.. Aliment Pharmacol Ther 1999;13:521–30.
  37. Odabasoglu F, Halici Z, Cakir A, Halici M, Aygun H, Suleyman H. Beneficial effects of vegetable oils (corn, olive and sunflower oils) and α‐tocopherol on anti‐inflammatory and gastrointestinal profiles of indomethacin in rats.. Eur J Pharmacol 2008;591:300–6.
  38. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID‐induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.. Gastroenterology 2000;119:706–14.
  39. Takeuchi K, Yasuhiro T, Asada Y, Sugawa Y. Role of nitric oxide in pathogenesis of aspirin‐induced gastric mucosal damage in rats.. Digestion 1998;59:298–307.
  40. Devi RS, Narayan S, Vani G, Shyamala Devi CS. Gastroprotective effect of Terminalia arjuna bark on diclofenac sodium induced gastric ulcer.. Chem Biol Interact 2007;167:71–83.
  41. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994;344:721–4.
  42. Basivireddy J, Jacob M, Ramamoorthy P, Pulimood AB, Balasubramanian KA. Indomethacin‐induced free radical‐mediated changes in the intestinal brush border membranes.. Biochem Pharmacol 2003;65:683–95.
  43. Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia.. Prostaglandins Leukot Essent Fatty Acids 1996;55:45–54.
  44. Stepan V, Sugano K, Yamada T, Park J, Dickinson CJ. Gastrin biosynthesis in canine G cells.. American journal of physiology‐gastrointestinal and liver Phys Ther 2002;282:G766–75.
  45. Beltinger J, Hildebrand P, Drewe J, Christ A, Hlobil K, Ritz M. Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans.. Eur J Clin Invest 1999;29:153–9.
  46. Walsh JH, Richardson CT, Fordtran JS. pH dependence of acid secretion and gastrin release in normal and ulcer subjects.. J Clin Invest 1975;55:462–8.
  47. Johnson LR. Apoptosis in the gastrointestinal tract.. Physiology of the gastrointestinal tract. London, UK, Waltham, MA and San Diego, CA: Academic Press; 2006.
  48. García‐Sancho M, Rodríguez‐Franco F, Sainz A, Rodríguez A, Silván G, Illera JC. Serum gastrin in canine chronic lymphocytic‐plasmacytic enteritis.. Can Vet J 2005;46:630–4.
  49. Mohamadkhani A, Darvish Moghaddam S, Salmanroghani H, Allafsghari A, Yazdanbod A, Mirzaei M. Are the serum biomarkers pepsinogen I and II good predictors for the detection of subjects with atrophic gastritis in areas that have different gastric cancer incidence?. Arch Iran Med 2013;16:208–12.
  50. Yusuf FS. Formulation and in‐vitro evaluation of floating microballoons of stavudine.. Univ J Pharm Res 2016;1:13–9.
  51. Zhang XM, Li JX, Zhang GY, Li XH, Gu H. The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China.. BMC Gastroenterol 2014;14:3.
  52. Ning P, Sun L, Liu H, Yuan Y. Expression of pepsinogen C in gastric cancer and precancerous diseases and its clinical significance.. Chin J Clin Oncol 2004;1:422–6.
  53. Miki K. Gastric cancer screening using the serum pepsinogen test method.. Gastric Cancer 2006;9:245–53.
  54. Zhao Y, Li B, Bai D, Huang J, Shiraigo W, Yang L. Comparison of fecal microbiota of Mongolian and thoroughbred horses by high‐throughput sequencing of the V4 region of the 16S rRNA gene.. Asian‐Australas J Anim Sci 2016;29(9):1345–52.
  55. Jinlian L, Lai M, Youfei S. Evaluation of genetic diversity of Mongolian horse and thoroughbred horse using microsatellite markers.. Acta Vet Zootechnic Sin 2005;36(1):6–9.
  56. Qirigeri Z, Hong Y, Dong‐yi B, Bei L, Lai M, Yi‐ping Z. Comparative analysis of blood biochemical, immune and antioxidant indicators in Mongolian horse and thoroughbred.. Animal Husbandry Feed Sci 2016;37(11):15–7.
Subscribe to our newsletter
Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.